Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries

Trial Profile

Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms DESSOLVE III
  • Most Recent Events

    • 06 Dec 2017 Results published in the Micell Technologies Media Release
    • 06 Dec 2017 According to a Micell Technologies media release, results from this trila was publised in the Lancet Medical Journal.
    • 01 Dec 2017 Primary endpoint (Non inferiority comparison of a device oriented composite endpoint (DOCE) or Target Lesion Failure (TLF) of the MISTENT group to the XIENCE group) has been met, according to the results published in The Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top